Article

Diet, Nutrition and prevention of cancer

Department of Nutrition , Harvard University, Cambridge, Massachusetts, United States
Public Health Nutrition (Impact Factor: 2.68). 03/2004; 7(1A):187-200. DOI: 10.1079/PHN2003588
Source: PubMed

ABSTRACT

To assess the epidemiological evidence on diet and cancer and make public health recommendations.
Review of published studies, concentrating on recent systematic reviews, meta-analyses and large prospective studies.
Overweight/obesity increases the risk for cancers of the oesophagus (adenocarcinoma), colorectum, breast (postmenopausal), endometrium and kidney; body weight should be maintained in the body mass index range of 18.5-25 kg/m(2), and weight gain in adulthood avoided. Alcohol causes cancers of the oral cavity, pharynx, oesophagus and liver, and a small increase in the risk for breast cancer; if consumed, alcohol intake should not exceed 2 units/d. Aflatoxin in foods causes liver cancer, although its importance in the absence of hepatitis virus infections is not clear; exposure to aflatoxin in foods should be minimised. Chinese-style salted fish increases the risk for nasopharyngeal cancer, particularly if eaten during childhood, and should be eaten only in moderation. Fruits and vegetables probably reduce the risk for cancers of the oral cavity, oesophagus, stomach and colorectum, and diets should include at least 400 g/d of total fruits and vegetables. Preserved meat and red meat probably increase the risk for colorectal cancer; if eaten, consumption of these foods should be moderate. Salt preserved foods and high salt intake probably increase the risk for stomach cancer; overall consumption of salt preserved foods and salt should be moderate. Very hot drinks and foods probably increase the risk for cancers of the oral cavity, pharynx and oesophagus; drinks and foods should not be consumed when they are scalding hot. Physical activity, the main determinant of energy expenditure, reduces the risk for colorectal cancer and probably reduces the risk for breast cancer; regular physical activity should be taken.

Download full-text

Full-text

Available from: Naomi E Allen
  • Source
    • "Plant bioactives fall under following major categories, i.e. fatty acids (ω-3 fatty acids), carotenoids (αcarotene , β-carotene, β-cryptoxanthin, lycopene, lutein and zeaxanthin), antioxidants (tocopherols, flavonoids, betalain and polyphenols), flavonoids (flavonols, flavan-3-ols, flavones , flavanones and anthocyanidins), glucosinolates, phytoestrogens (isoflavones and lignans), sulphur containing bioactive compounds, terpenoids, dietary fibres, fat soluble vitamins (A, D, E and K) and phytosterols (stigmasterol, βsitosterol and campesterol). Bioactive compounds belong to 'non-nutritive' group and have been shown to provide protection against oxidative degenerative diseases like coronary heart disease (Joshipura et al. 2001;Dauchet et al. 2006), cardiovascular disease (Hung et al. 2004), ischaemic stroke (Joshipura et al. 1999;Tavani et al. 2006), cancer (Khaw et al. 2001;WHO/FAO, 2002;Key et al. 2004a;Key et al. 2004b;Hoensch and Kirch 2005;van Gils et al. 2005), Alzheimer's disease (Danny and Buttriss 2005) and lung disorders such as obstructive pulmonary disease (Denny et al. 2003). There is a growing need of incorporation of such bioactive compounds in functional foods, but this poses several challenges for the researchers because of the physical and chemical instability when extracted from its source. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bioactives have shown excellent protective effect against chronic diseases such as cancer, cardiovascular diseases and metabolic disorders. However, many of the bioactives like anthocyanins, carotenoids, flavonoids, vitamins and essential fatty acids are sensitive to surrounding environment stresses like pH, ionic strength, light, temperature, oxygen and gastro-intestinal (GI) conditions during transit. Hence, the functionality diminishes upon exposure to such unfriendly environment and leads to reduction in bioavailability. Double emulsions are designed to provide protection to bioactives in the innermost compartment through encapsulation and prevent loss of functionality in food matrix as well as during the GI transit. This article reviews the work done on double emulsion for food applications, covering various aspects of double emulsion like its matrix, constituents (aqueous phase, oil phase, emulsifiers, and other additives) and properties (viscosity, particle size, electrical conductivity and zeta potential). In addition to the stability of double emulsion, various means to express and modern techniques to measure it, the review also elucidates the role of newer emulsifiers and additives in improving the stability of double emulsion. The developments in target delivery of bioactives through double emulsion are highlighted. In vitro and in vivo studies proved target delivery of bioactives through double emulsion; however, confirmation through human trial is still pending.
    Preview · Article · Apr 2015 · Food and Bioprocess Technology
  • Source
    • "Diet is a key player in the progression and pathogenesis of cancer. While high-calorie and high-fat diets are associated with increased incidence of cancer [59], several epidemiological studies have demonstrated a direct relationship between low-sugar diet and a lower incidence of cancer [60]. Our study indicates a reduced tumor growth and tumor weight, along with a reduced proliferation of tumor cells in tumor-bearing mice that were subjected to a ketogenic diet relative to regular chow. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Aberrant energy metabolism is a hallmark of cancer. To fulfill the increased energy requirements, tumor cells secrete cytokines/factors inducing muscle and fat degradation in cancer patients, a condition known as cancer cachexia. It accounts for nearly 20% of all cancer-related deaths. However, the mechanistic basis of cancer cachexia and therapies targeting cancer cachexia thus far remain elusive. A ketogenic diet, a high-fat and low-carbohydrate diet that elevates circulating levels of ketone bodies (i.e., acetoacetate, β-hydroxybutyrate, and acetone), serves as an alternative energy source. It has also been proposed that a ketogenic diet leads to systemic metabolic changes. Keeping in view the significant role of metabolic alterations in cancer, we hypothesized that a ketogenic diet may diminish glycolytic flux in tumor cells to alleviate cachexia syndrome and, hence, may provide an efficient therapeutic strategy. Results We observed reduced glycolytic flux in tumor cells upon treatment with ketone bodies. Ketone bodies also diminished glutamine uptake, overall ATP content, and survival in multiple pancreatic cancer cell lines, while inducing apoptosis. A decrease in levels of c-Myc, a metabolic master regulator, and its recruitment on glycolytic gene promoters, was in part responsible for the metabolic phenotype in tumor cells. Ketone body-induced intracellular metabolomic reprogramming in pancreatic cancer cells also leads to a significantly diminished cachexia in cell line models. Our mouse orthotopic xenograft models further confirmed the effect of a ketogenic diet in diminishing tumor growth and cachexia. Conclusions Thus, our studies demonstrate that the cachectic phenotype is in part due to metabolic alterations in tumor cells, which can be reverted by a ketogenic diet, causing reduced tumor growth and inhibition of muscle and body weight loss.
    Full-text · Article · Sep 2014
  • Source
    • "Identifying the potential for societal welfare gains from disease prevention requires an understanding of what people at risk value when making their choices, and why they value certain factors more than others. The most important determinants of health are related to individual behaviour, including individuals’ choices and trade-offs that may significantly affect their health [14, 15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Patients’ perception of risk and their lifestyle choices are of major importance in the treatment of common chronic diseases. This study reveals determinants for and knowledge about why people accept or reject preventive medical interventions against heart disease. Methods A representative sample of 40-60-year-old Danish inhabitants was invited to participate in a web-based survey. The respondents were presented with a hypothetical scenario and asked to imagine that they were at an increased risk of heart disease, and subsequently presented with an offer of a preventive medical intervention. The aim was to elicit preference structures when potential patients are presented with different treatment conditions. Results About one third of the respondents were willing to accept preventive medical treatment. Respondents with personal experience with heart disease were more likely to accept treatment than respondents with family members with heart disease or no prior experience with heart disease. The willingness to accept treatment was similar for both genders, and when adjusting for experience with heart disease, age was not associated with willingness to accept treatment. Socioeconomic status in terms of lower education was positively associated with acceptance. The price of treatment reduced willingness to accept for the lower income groups, whereas it had no effect in the highest income group. Some 57% of respondents who were willing to accept treatment changed their decision following information on potential side effects. Conclusions In accordance with our pre-study hypothesis, individuals with low income were more sensitive to price than individuals with high income. Thus, if the price of preventive medication increases above certain limits, a substantial proportion of the population may refrain from treatment. More than half of the respondents who were initially willing to accept treatment changed their decision when informed about the presence of potential side effects. This is an important observation in relation to risk communication, since most side effects occur very seldom, and a skewed assessment of treatment efficacy compared to risk of side effects may refrain some patients from treatment. Thus, more research is needed to better allow patients to compare treatment efficacy with risk of side effects in quantitative terms.
    Full-text · Article · Aug 2014 · BMC Public Health
Show more